Ornidol O Tablet is a combination antibiotic formulation containing Ofloxacin 200mg and Ornidazole 500mg, designed for the treatment of mixed bacterial and protozoal infections. Ofloxacin, a fluoroquinolone antibiotic, exerts its bactericidal effect by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription in susceptible organisms. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by causing DNA strand breakage and inhibiting nucleic acid synthesis. This synergistic combination is indicated for infections where both aerobic and anaerobic pathogens are involved, including gastrointestinal infections, genitourinary tract infections, respiratory tract infections, skin and soft tissue infections, and certain sexually transmitted infections. The dual action ensures broad-spectrum coverage against a wide range of pathogens. Ornidol O Tablet should be administered as prescribed by a healthcare professional, with dosage adjusted according to the severity of infection and patient-specific factors such as renal function. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and use during pregnancy and lactation should be under strict medical supervision. Adverse effects may include gastrointestinal disturbances, headache, dizziness, and, rarely, hypersensitivity reactions. Proper adherence to the prescribed regimen is essential to prevent resistance development.